Armand Balboni's guest appearances

Armand Balboni

The John Batchelor Show

Finding Genius Podcast

David Berlinski

Max Planck Institute

James Shapiro

Joseph Warren

Bob Zimmerman

David Henderson

David Brady

Chris Smith

Marc Bekoff

Matt Richtel

David Quammen

Jessica Pierce

Johns Hopkins

Hillary Clinton

Amanda Foreman

OwlTail

Photo: No known restrictions on publication.1917. Canada, Nova Scotia, Halifax--View of waterfront http://JohnBatchelorShow.com/contacthttp://JohnBatchelorShow.com/schedulesParler &amp; Twitter: @BatchelorShowDeveloping a therapeutic for the most vulnerable in the first 48 hours of testing positive for the coronavirus. Armand Balboni, MD, PhD CEO Appili Therapeutics. Canada TSX: APLI.  US OTC: APLIFhttps://www.appilitherapeutics.com/business-environmentArmand Balboni, MD, PhD Chief Executive Officer​Armand Balboni's career includes medical research and drug development experience in civilian, academic and military organizations, most recently as a partner at Bloom Burton &amp; Co. where he was the firms senior advisor for regulatory and medical affairs. As an active duty military officer, Dr. Balboni served as a staff officer at the U.S. Army Research Institute of Infectious Diseases (USAMRIID). He completed a military staff fellowship at the U.S. Food and Drug Administration and went on to serve as the deputy director of clinical and regulatory affairs for the U.S. Army. Armand completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School. .

Photo: No known restrictions on publication.1917. <h1>Canada, Nova Scotia, Halifax--View of waterfront</h1> <a href="http://JohnBatchelorShow.com/contact" rel="nofollow" target="_blank">http://JohnBatchelorShow.com/contact</a> <a href="http://JohnBatchelorShow.com/schedules" rel="nofollow" target="_blank">http://JohnBatchelorShow.com/schedules</a> Parler &amp; Twitter: @BatchelorShow Developing a therapeutic for the most vulnerable in the first 48 hours of testing positive for the coronavirus. Armand Balboni, MD, PhD CEO Appili Therapeutics. Canada TSX: APLI.  US OTC: APLIF <a href="https://www.appilitherapeutics.com/business-environment" rel="nofollow" target="_blank">https://www.appilitherapeutics.com/business-environment </a> Armand Balboni, MD, PhD Chief Executive Officer​Armand Balboni's career includes medical research and drug development experience in civilian, academic and military organizations, most recently as a partner at Bloom Burton &amp; Co. where he was the firms senior advisor for regulatory and medical affairs. As an active duty military officer, Dr. Balboni served as a staff officer at the U.S. Army Research Institute of Infectious Diseases (USAMRIID). He completed a military staff fellowship at the U.S. Food and Drug Administration and went on to serve as the deputy director of clinical and regulatory affairs for the U.S. Army. Armand completed his doctoral work in the MD/PhD program at the Icahn School of Medicine at Mount Sinai and earned his law degree at Brooklyn Law School. .

738: Developing a therapeutic for the most vulnerable in the first 48 hours of testing positive for the coronavirus. Armand Balboni, MD, PhD CEO Appili Therapeutics. Canada TSX: APLI.  US OTC: APLIF

Efforts to stop SARS-CoV-2 in its tracks have been ongoing for months, and now there might be something tangible that makes it happen.  Press play to learn:  How to trigger viral mutations that prevent SARS-CoV-2 from replicating in the human body, thereby preventing the “cytokine storm” associated with COVID-19 COVID-19 prophylaxis in communities that may need it the most? Whether it’s possible, and how it's being investigated What’s necessary in order to warrant emergency use authorization for an antiviral drug in treating COVID-19    Fueled by a long-standing fascination with  infectious diseases and pandemics like the Black Death, Dr. Armand Balboni earned a dual MD/PhD degree at Mount Sinai School of Medicine in New York. Having spent 17 years in the US military as an officer working on a number of  infectious diseases including Ebola, dengue fever, and malaria, he discovered unmet needs in the marketplace, and wanted to design a socially-conscious company to meet those needs. In 2014, this goal manifested as Appili Therapeutics, a pure play anti-infectives company. Today, the team at Appili Therapeutics is working on phase II and phase III clinical trials for the most advanced product that is an oral tablet for COVID-19: an antiviral medication called favipiravir. This medication has already undergone three phase III clinical trials in the US and been approved for pandemic flu in Japan and China. The expectation is that the current phase II and phase III clinical trials will show that favipiravir is safe and effective specifically for the treatment of COVID-19. Dr. Balboni anticipates that this medication will be available for use against COVID-19 by early next year. Dr. Balboni explains the importance of each stage in the US clinical trial process, the specific mechanism of action by which favipiravir works against viral replication, Operation Warp Speed as it applies to both vaccines and therapeutic drugs, possible side effects of favipiravir, and more. Visit https://clinicaltrials.gov/ and https://www.appilitherapeutics.com/ for more information.  Available on Apple Podcasts: apple.co/2Os0myK

Efforts to stop SARS-CoV-2 in its tracks have been ongoing for months, and now there might be something tangible that makes it happen. Press play to learn: <ul> <li>How to trigger viral mutations that prevent SARS-CoV-2 from replicating in the human body, thereby preventing the “cytokine storm” associated with COVID-19</li> <li>COVID-19 prophylaxis in communities that may need it the most? Whether it’s possible, and how it's being investigated</li> <li>What’s necessary in order to warrant emergency use authorization for an antiviral drug in treating COVID-19  </li> </ul> Fueled by a long-standing fascination with <a href="https://www.findinggeniuspodcast.com/podcasts/infectious-diseases-expert-dr-james-shepherd-offers-global-perspective/" rel="nofollow" target="_blank"> infectious diseases</a> and pandemics like the Black Death, Dr. Armand Balboni earned a dual MD/PhD degree at Mount Sinai School of Medicine in New York. Having spent 17 years in the US military as an officer working on a number of <a href="https://www.findinggeniuspodcast.com/podcasts/inspecting-the-spread-and-management-of-infectious-diseases-mark-lurie-associate-professor-of-epidemiology-brown-university/" rel="nofollow" target="_blank"> infectious diseases</a> including Ebola, dengue fever, and malaria, he discovered unmet needs in the marketplace, and wanted to design a socially-conscious company to meet those needs. In 2014, this goal manifested as Appili Therapeutics, a pure play anti-infectives company. Today, the team at Appili Therapeutics is working on phase II and phase III clinical trials for the most advanced product that is an oral tablet for COVID-19: an antiviral medication called favipiravir. This medication has already undergone three phase III clinical trials in the US and been approved for pandemic flu in Japan and China. The expectation is that the current phase II and phase III clinical trials will show that favipiravir is safe and effective specifically for the treatment of COVID-19. Dr. Balboni anticipates that this medication will be available for use against COVID-19 by early next year. Dr. Balboni explains the importance of each stage in the US clinical trial process, the specific mechanism of action by which favipiravir works against viral replication, Operation Warp Speed as it applies to both vaccines and therapeutic drugs, possible side effects of favipiravir, and more. Visit <a href="https://clinicaltrials.gov/" rel="nofollow" target="_blank">https://clinicaltrials.gov/</a> and <a href="https://www.appilitherapeutics.com/" rel="nofollow" target="_blank">https://www.appilitherapeutics.com/</a> for more information. Available on Apple Podcasts: <a href="https://podcasts.apple.com/us/podcast/id1169016854" rel="nofollow" target="_blank">apple.co/2Os0myK</a>

An Effective Oral Tablet For COVID-19? Armand Balboni, MD, PhD Discusses